JANTOVEN

Post-LOE

warfarin sodium

Molecular Devices

ANDAORALTABLET

Approved

Oct 2003

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

JANTOVEN (warfarin sodium) by Molecular Devices is k-dependent clotting factors, which include factors ii, vii, ix, and x, and the anticoagulant proteins c and s. Approved for pulmonary embolism, atrial fibrillation, further extension of the formed clot and 2 more indications. First approved in 2003.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

K-dependent clotting factors, which include Factors II, VII, IX, and X, and the anticoagulant proteins C and S. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K-dependent clotting factors. Vitamin K promotes the biosynthesis of γ-carboxyglutamic acid residues in…

Indications (5)

pulmonary embolism atrial fibrillation

Worked on JANTOVEN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.